Table 8.

Interaction of all examined markers with paclitaxel treatment in terms of DFS and OS

	DFS			OS
	HR	95% CI	Wald’s p	HR	95% CI	Wald’s p
alphaB-crystallin * Treatment			0.72			0.75
alphaB-crystallin neg vs. pos in non-paclitaxel treated	1.21	0.48-3.01		0.88	0.35-2.23
alphaB-crystallin neg vs. pos in paclitaxel treated	0.81	0.53-1.24		0.60	0.38-0.97
Non-paclitaxel treated vs. paclitaxel treated in alphaB-crystallin neg	1.23	0.92-1.63		1.35	0.97-1.86
Non-paclitaxel treated vs. paclitaxel treated in alphaB-crystallin pos	0.82	0.31-2.17		0.93	0.35-2.47
BRCA1 * Treatment			0.55			0.99
BRCA1 neg vs. pos in non-paclitaxel treated	1.43	0.34-5.91		1.01	0.24-4.20
BRCA1 neg vs. pos in paclitaxel treated	0.96	0.61-1.49		1.02	0.59-1.77
Non-paclitaxel treated vs. paclitaxel treated in BRCA1 neg	1.19	0.90-1.58		1.29	0.94-1.78
Non-paclitaxel treated vs. paclitaxel treated in BRCA1 pos	0.79	0.18-3.43		1.31	0.29-5.85
BRCA1 * Treatment			0.37			0.48
BRCA1 WT vs. mut in non-paclitaxel treated1	.	.		.	.
BRCA1 WT vs. mut in paclitaxel treated	0.61	0.21-1.76		0.64	0.19-2.17
Non-paclitaxel treated vs. paclitaxel treated in BRCA1 WT	0.76	0.25-2.25		0.29	0.06-1.37
Non-paclitaxel treated vs. paclitaxel treated in BRCA1 mut1	.	.		.	.
p53 * Treatment			0.35			0.58
p53 neg vs. pos in non-paclitaxel treated	1.06	0.61-1.84		0.94	0.50-1.78
p53 neg vs. pos in paclitaxel treated	0.80	0.63-1.02		0.77	0.58-1.03
Non-paclitaxel treated vs. paclitaxel treated in p53 neg	1.36	0.82-2.23		1.37	0.76-2.47
Non-paclitaxel treated vs. paclitaxel treated in p53 pos	1.02	0.72-1.43		1.13	0.77-1.65

*: interaction; ¹: There were no patients with BRCA1 mutations in the non-paclitaxel treated group.

HR, hazard ratio; CI, confidence interval; pos, positive; neg, negative; mut, mutated; WT, wild-type.